T-Lymphoblastic Leukemia / Lymphoma · line 2 · Nelarabine monotherapy for r/r T-ALL/T-LBL (adult dosing)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-NELARABINE-TCELL`

ID	`IND-T-ALL-2L-NELARABINE`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-T-ALL`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025`

Notes

STUB. Major UA access barrier — international supply required. Always plan as bridge to alloSCT in fit; palliative if not.

Used By

Algorithms

ALGO-T-ALL-2L - ALGO-T-ALL-2L